Kymera Therapeutics, Inc.KYMRNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -20.88% | -84.56% | +114.83% | -55.26% | -26.12% |
| Gross Profit Growth | -20.88% | -84.56% | +114.83% | -63.38% | -2006.71% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +30.30% | +36.68% | +13.25% | +10.12% | +14.68% |
| Weighted Average Shares Diluted Growth | +30.30% | +36.68% | +13.25% | +10.12% | +14.68% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -867.98% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -65.14% | -94.95% | +885.22% | +2247.42% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +87.34% | +69.87% | +5.77% | +36.93% | +6.49% |
| Book Value per Share Growth | +73.25% | +54.79% | -2.38% | +28.81% | -7.59% |
| Debt Growth | +9.14% | +3.65% | -0.79% | -2.80% | -4.80% |
| R&D Expense Growth | +25.55% | +35.58% | +64.39% | +32.41% | +22.65% |
| SG&A Expenses Growth | +9.45% | +14.80% | +13.20% | +1.57% | +12.17% |